Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications.
Clinical trial NCT04218266 · COMPLETED
Trial details
- NCT number
- NCT04218266
- Sponsor
- Bayer
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-01-30
- Primary completion
- 2021-10-08
- Enrollment
- 755
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.